PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling

S. W. Huang, J. C. Lien, S. C. Kuo, T. F. Huang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and Purpose Angiogenesis contributes to coronary heart disease, immune disorders and numerous malignancies. VEGF-A and its receptors (VEGFRs) play a pivotal role in regulating angiogenesis. In an effort to discover more effective inhibitors of tumour angiogenesis, we have analysed the actions of a novel anthraquinone derivative, PPemd26, and explored its anti-angiogenic mechanisms.

Experimental Approach The effects of PPemd26 were evaluated in vitro using HUVEC cultures to assess proliferation, migration, invasion and tube formation. Immunoblotting was used to analyse phosphorylation of signalling kinases. Effects in vivo were assayed using Matrigel plug and xenograft mouse models.

Key Results PPemd26 significantly inhibited VEGF-A-induced proliferation, migration, invasion and tube formation of HUVECs. PPemd26 also attenuated VEGF-A-induced microvessel sprouting from rat aortic rings ex vivo and suppressed formation of new blood vessels in implanted Matrigel plugs in models of angiogenesis in vivo. In addition, PPemd26 inhibited VEGF-A-induced phosphorylation of VEGFR2 and its downstream protein kinases including Akt, focal adhesion kinase, ERK and Src. Furthermore, systemic administration of PPemd26 suppressed the growth of s.c. xenografts of human colon carcinoma in vivo. Histochemical analysis of the xenografts revealed a marked reduction in stainingfor the vascular marker CD31 and proliferation marker Ki-67.

Conclusions and Implications This study provides evidence that PPemd26 suppressed tumour angiogenesis through inhibiting VEGFR2 signalling pathways, suggesting that PPemd26 is a potential drug candidate for developing anti-angiogenic agents for the treatment of cancer and angiogenesis-related diseases.

Original languageEnglish
Pages (from-to)5728-5742
Number of pages15
JournalBritish Journal of Pharmacology
Volume171
Issue number24
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Anthraquinones
Vascular Endothelial Growth Factor A
Heterografts
Blood Vessels
Phosphorylation
Focal Adhesion Protein-Tyrosine Kinases
Neoplasms
Angiogenesis Inhibitors
Second Primary Neoplasms
Immune System Diseases
Microvessels
Immunoblotting
Protein Kinases
Coronary Disease
Colon
Phosphotransferases
Carcinoma
Growth
Pharmaceutical Preparations
matrigel

ASJC Scopus subject areas

  • Pharmacology

Cite this

PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling. / Huang, S. W.; Lien, J. C.; Kuo, S. C.; Huang, T. F.

In: British Journal of Pharmacology, Vol. 171, No. 24, 01.01.2014, p. 5728-5742.

Research output: Contribution to journalArticle

Huang, S. W. ; Lien, J. C. ; Kuo, S. C. ; Huang, T. F. / PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling. In: British Journal of Pharmacology. 2014 ; Vol. 171, No. 24. pp. 5728-5742.
@article{7c6a7913bb434055831d764298e150e2,
title = "PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling",
abstract = "Background and Purpose Angiogenesis contributes to coronary heart disease, immune disorders and numerous malignancies. VEGF-A and its receptors (VEGFRs) play a pivotal role in regulating angiogenesis. In an effort to discover more effective inhibitors of tumour angiogenesis, we have analysed the actions of a novel anthraquinone derivative, PPemd26, and explored its anti-angiogenic mechanisms.Experimental Approach The effects of PPemd26 were evaluated in vitro using HUVEC cultures to assess proliferation, migration, invasion and tube formation. Immunoblotting was used to analyse phosphorylation of signalling kinases. Effects in vivo were assayed using Matrigel plug and xenograft mouse models.Key Results PPemd26 significantly inhibited VEGF-A-induced proliferation, migration, invasion and tube formation of HUVECs. PPemd26 also attenuated VEGF-A-induced microvessel sprouting from rat aortic rings ex vivo and suppressed formation of new blood vessels in implanted Matrigel plugs in models of angiogenesis in vivo. In addition, PPemd26 inhibited VEGF-A-induced phosphorylation of VEGFR2 and its downstream protein kinases including Akt, focal adhesion kinase, ERK and Src. Furthermore, systemic administration of PPemd26 suppressed the growth of s.c. xenografts of human colon carcinoma in vivo. Histochemical analysis of the xenografts revealed a marked reduction in stainingfor the vascular marker CD31 and proliferation marker Ki-67.Conclusions and Implications This study provides evidence that PPemd26 suppressed tumour angiogenesis through inhibiting VEGFR2 signalling pathways, suggesting that PPemd26 is a potential drug candidate for developing anti-angiogenic agents for the treatment of cancer and angiogenesis-related diseases.",
author = "Huang, {S. W.} and Lien, {J. C.} and Kuo, {S. C.} and Huang, {T. F.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/bph.12872",
language = "English",
volume = "171",
pages = "5728--5742",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "John Wiley and Sons Inc.",
number = "24",

}

TY - JOUR

T1 - PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling

AU - Huang, S. W.

AU - Lien, J. C.

AU - Kuo, S. C.

AU - Huang, T. F.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background and Purpose Angiogenesis contributes to coronary heart disease, immune disorders and numerous malignancies. VEGF-A and its receptors (VEGFRs) play a pivotal role in regulating angiogenesis. In an effort to discover more effective inhibitors of tumour angiogenesis, we have analysed the actions of a novel anthraquinone derivative, PPemd26, and explored its anti-angiogenic mechanisms.Experimental Approach The effects of PPemd26 were evaluated in vitro using HUVEC cultures to assess proliferation, migration, invasion and tube formation. Immunoblotting was used to analyse phosphorylation of signalling kinases. Effects in vivo were assayed using Matrigel plug and xenograft mouse models.Key Results PPemd26 significantly inhibited VEGF-A-induced proliferation, migration, invasion and tube formation of HUVECs. PPemd26 also attenuated VEGF-A-induced microvessel sprouting from rat aortic rings ex vivo and suppressed formation of new blood vessels in implanted Matrigel plugs in models of angiogenesis in vivo. In addition, PPemd26 inhibited VEGF-A-induced phosphorylation of VEGFR2 and its downstream protein kinases including Akt, focal adhesion kinase, ERK and Src. Furthermore, systemic administration of PPemd26 suppressed the growth of s.c. xenografts of human colon carcinoma in vivo. Histochemical analysis of the xenografts revealed a marked reduction in stainingfor the vascular marker CD31 and proliferation marker Ki-67.Conclusions and Implications This study provides evidence that PPemd26 suppressed tumour angiogenesis through inhibiting VEGFR2 signalling pathways, suggesting that PPemd26 is a potential drug candidate for developing anti-angiogenic agents for the treatment of cancer and angiogenesis-related diseases.

AB - Background and Purpose Angiogenesis contributes to coronary heart disease, immune disorders and numerous malignancies. VEGF-A and its receptors (VEGFRs) play a pivotal role in regulating angiogenesis. In an effort to discover more effective inhibitors of tumour angiogenesis, we have analysed the actions of a novel anthraquinone derivative, PPemd26, and explored its anti-angiogenic mechanisms.Experimental Approach The effects of PPemd26 were evaluated in vitro using HUVEC cultures to assess proliferation, migration, invasion and tube formation. Immunoblotting was used to analyse phosphorylation of signalling kinases. Effects in vivo were assayed using Matrigel plug and xenograft mouse models.Key Results PPemd26 significantly inhibited VEGF-A-induced proliferation, migration, invasion and tube formation of HUVECs. PPemd26 also attenuated VEGF-A-induced microvessel sprouting from rat aortic rings ex vivo and suppressed formation of new blood vessels in implanted Matrigel plugs in models of angiogenesis in vivo. In addition, PPemd26 inhibited VEGF-A-induced phosphorylation of VEGFR2 and its downstream protein kinases including Akt, focal adhesion kinase, ERK and Src. Furthermore, systemic administration of PPemd26 suppressed the growth of s.c. xenografts of human colon carcinoma in vivo. Histochemical analysis of the xenografts revealed a marked reduction in stainingfor the vascular marker CD31 and proliferation marker Ki-67.Conclusions and Implications This study provides evidence that PPemd26 suppressed tumour angiogenesis through inhibiting VEGFR2 signalling pathways, suggesting that PPemd26 is a potential drug candidate for developing anti-angiogenic agents for the treatment of cancer and angiogenesis-related diseases.

UR - http://www.scopus.com/inward/record.url?scp=84919359716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919359716&partnerID=8YFLogxK

U2 - 10.1111/bph.12872

DO - 10.1111/bph.12872

M3 - Article

VL - 171

SP - 5728

EP - 5742

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 24

ER -